Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Pfizer-Sanofi match not made in heaven?
Say the Pfizer/Sanofi-Aventis rumors are true: Would merging with the French drug maker boost Pfizer's fortunes? Not so much, say some observers.
The two companies do have some strengths in common--particularly their cardiovascular and central nervous system products. But they also share weaknesses. Some of their major patents would expire in tandem, for instance; Pfizer's blockbuster Lipitor goes off patent in 2012, and 2011 is D-Day for Sanofi-Aventis' Plavix (which it markets along with Bristol-Myers Squibb). So they also share a need for new big-selling products. And really--would the French easily relinquish one of their business jewels to American sway?
- read the Dow Jones column
Related Articles:
Sanofi stock up on Pfizer buyout talk. Report
Pfizer, Wyeth merger bad idea? Report
Read more on: Pfizer | Sanofi-Aventis
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
